Novel targeted therapy beyond EGFR and ALK: ROS1, BRAF, RET and MET

被引：0
|
作者：
Yoh, Kiyotaka [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz328
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY10 - 2
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer
    Farago, Anna F.
    Azzoli, Christopher G.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (05) : 550 - 559
  • [2] MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
    Jordana, N.
    Esparre, C.
    Roman, R.
    Aguado, C.
    Garcia, B.
    Vives, M.
    Marin, E.
    Garcia-Roman, S.
    Aguilar, A.
    Reguart, N.
    Rosell, R.
    Molina-Vila, M. A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S459 - S459
  • [3] Frequency of Driver Genes (EGFR, KRAS, BRAF, ALK, RET and ROS1) Alterations in Brazilian Patients with Lung Adenocarcinoma
    Campanha Novaes, L.
    Cavagna, R.
    De Paula, F.
    De Marchi, P.
    Zanon Da Silva, M.
    Evangelista, A.
    Sussuchi Da Silva, L.
    Albino Da Silva, E.
    Leal, L.
    Reis, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S685 - S685
  • [4] RET, ROS1 and ALK fusions in lung cancer
    Kengo Takeuchi
    Manabu Soda
    Yuki Togashi
    Ritsuro Suzuki
    Seiji Sakata
    Satoko Hatano
    Reimi Asaka
    Wakako Hamanaka
    Hironori Ninomiya
    Hirofumi Uehara
    Young Lim Choi
    Yukitoshi Satoh
    Sakae Okumura
    Ken Nakagawa
    Hiroyuki Mano
    Yuichi Ishikawa
    Nature Medicine, 2012, 18 : 378 - 381
  • [5] RET, ROS1 and ALK fusions in lung cancer
    Takeuchi, Kengo
    Soda, Manabu
    Togashi, Yuki
    Suzuki, Ritsuro
    Sakata, Seiji
    Hatano, Satoko
    Asaka, Reimi
    Hamanaka, Wakako
    Ninomiya, Hironori
    Uehara, Hirofumi
    Choi, Young Lim
    Satoh, Yukitoshi
    Okumura, Sakae
    Nakagawa, Ken
    Mano, Hiroyuki
    Ishikawa, Yuichi
    NATURE MEDICINE, 2012, 18 (03) : 378 - 381
  • [6] Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC
    Li, Weihua
    Guo, Lei
    Liu, Yutao
    Dong, Lin
    Yang, Lin
    Chen, Li
    Liu, Kaihua
    Shao, Yang
    Ying, Jianming
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 404 - 418
  • [7] Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
    Kohno, Takashi
    Nakaoku, Takashi
    Tsuta, Koji
    Tsuchihara, Katsuya
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Goto, Koichi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (02) : 156 - 164
  • [8] Identification of Known and Novel ALK, RET and ROS1 Gene Fusions Using Archer Targeted Sequencing Technology
    O'Reilly, C.
    Song, W.
    Shah, R. H.
    Won, H.
    Nafa, K.
    Arcila, M. E.
    Ladanyi, M.
    Cheng, D. T.
    Berger, M.
    Benayed, R.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (06): : 752 - 752
  • [9] Multiplexed FISH (ALK/ROS1, RET, NTRK1) in Lung Adenocarcinomas: Novel Dual ALK/ROS1 Probe and Automated Scanning System
    Hernandez, Susana
    Conde, Esther
    Prieto, Mario
    Martinez, Rebeca
    Rodriguez, Margarita
    Martin, Raquel
    Jimenez, Luis
    Madrigal, Luis
    Angulo, Barbara
    Lopez-Rios, Fernando
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S513 - S514
  • [10] ALK, ROS1, and RET - Does the Partner Gene Matter?
    Lovly, Christine
    Childress, Merrida
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S128 - S129
12345